One of the common features of cystic cells derived from murine models of ADPKD is that they exhibit increased glucose uptake and lactate accumulation (9). In Pkd1^−/− cells, glucose is converted to pyruvate which is then reduced to lactate instead of being transported into mitochondria (9, 12). Metabolic tracing with ¹³C₆-glucose by NMR revealed a significant increase in lactate production in cystic kidneys compared to age-matched controls derived from an aggressive model (Ksp-Cre:Pkd1^flox/−) and a slowly progressive murine model (Tm-Cre:Pkd1^flox/−) of ADPKD (9). Increased glucose uptake was also found in Pkd1 mutant mouse embryonic kidney (MEK) cells compared with Pkd1 WT MEK cells (15). Further, an upregulation of glycolytic markers was observed (9, 15, 16), and the glycolytic signature was confirmed in a subset of human microarray data and cystic kidneys derived from hypomorphic Pkd1 mutant mice (9, 12, 17). A recent study investigated the cross-sectional association of urinary metabolic biomarkers with ADPKD (18) severity among the TAME-PKD trial participants at baseline (19) (Please refer to Table 1 for mentioned clinical trials). This study is the first evidence of human urine samples supporting that increasing ADPKD severity is associated with a metabolic shift toward increased aerobic glycolysis. Other studies on the analysis of biomarkers in ADPKD should follow as to determine the ability to detect if a particular biomarker changes with time and if the correlations may be associated with cellular damage rather than metabolic changes per se. The enhanced glycolysis, the so-called Warburg effect reminiscent of cancer cells (49), contributes to the metabolic re-wiring in ADPKD and is considered a prominent feature of this disease.

Mitochondria are the central organelles for metabolism and are the key players for energy production in the cells. Mitochondrial respiration has been reported to be altered in Pkd1^−/− proximal tubule cells (11). Indeed, the investigators demonstrated that oxygen levels regulate the localization and activity of PC1 by a prolyl hydroxylase domain-containing protein 3 (EGLN3). Furthermore, the study reported that the polycystin proteins localize in the mitochondria-associated membranes (MAMs), where they can mediate calcium signaling from the ER lumen to the mitochondrial matrix (11). PC2 depletion alters calcium transfer and decreases mitochondrial movement. This decrease is thought to be the result of an increased expression of the ER-mitochondrial tethering protein, mitofusin 2 (MFN2), which ultimate affecting calcium-mediated mitochondrial bioenergetics that contribute to cell proliferation (50). These findings collectively suggest that the polycystins are important regulators of mitochondrial function, but whether mitochondrial calcium and dynamics are disrupted in PKD1 mutations warrants further investigation. A cleaved carboxyl-terminal fragment of PC1 has been proposed to accumulate in mitochondria, indicating that PC1 may directly modulate mitochondrial function (51). However, how this cleavage is involved in cyst formation or mitochondrial function is still unknown.

Morphologically, abnormal mitochondria were described in cyst-lining cells in an ADPKD mouse model (Ksp-Cre:Pkd1^flox/flox) and in rats (Han:SPRD Cy/+) (52). This was accompanied by a reduction in mitochondrial number suggesting a decrease in mitochondrial mass in the cystic epithelia (52). In another study, the decrease in mitochondrial mass was found to be correlated with a reduced activity of mitochondrial respiratory enzymes and fragmentation of the mitochondrial network in the cystic epithelial of Ksp-Cre:Pkd1^flox/− kidneys (53). The inhibition of mitochondrial function was shown to be mediated by miR-17- Pparα axis (54). The miR-17 inhibits OXPHOS and fatty acid oxidation, and its suppression improves mitochondrial function of cyst epithelia (54). PPARγ, another member of the PPAR subfamily has been shown to be implicated in ADPKD pathogenesis. Moreover, treatment with PPARγ agonist rescues proliferation and retards cyst growth in rodent PKD models (55–57).

The master regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1α), was downregulated in kidney tissues from Pkd1^flox/flox and 7-week-old Cy/+ rats (52). PPARA and its target genes were shown to belong to a down regulated pathway in human ADPKD cysts (17). Interestingly, the mitochondria from PC2 knock-down (KD) cyst-modeling cells exhibit altered metabolic capacity and show a high degree of fragmentation, which they have in common with PKD1; however, an increased level in PCG-1α was shown in PC2 KD cells (50). The reasons for these different phenotypes between cells lacking PC1 and PC2 proteins still remains unclear, but the idea that mitochondria-ER communication is a common mechanism that contributes to altered metabolism in ADPKD is well-evidenced.

The major pathway for the degradation of fatty acids inside the mitochondria is mitochondrial fatty acid β-oxidation (FAO), which is the preferred energy source for highly metabolic cells and can contribute to mitochondrial dysfunction. Under physiological conditions, FAO provides more ATP than glucose oxidation (58). In Pkd1 knock-down cells derived from mouse cortical collecting duct (mCCD) and from immortalized proximal or distal tubule cells from Pkd1^cko/cko, the oxygen consumption rate (OCR) was reduced in the presence of palmitate compared to respective controls (10). The reduced FAO, observed by OCR, was shown in other cell lines derived from ADPKD mouse models (11, 12, 54). Often, this reduction is accompanied by increased fatty acid biosynthesis, which can favor the increased de novo fatty acid synthesis (FASN) and inhibit the increased synthesis of carnitine palmitoyl transferase 1 (CPT1) transporters into the mitochondria. This was observed in Pkd1^−/− cells and kidneys from Ksp-Cre:Pkd1^flox/− when compared to controls (12). These results suggest that fatty acids derived carbons sustain reductive carboxylation for the de novo fatty acids biosynthesis through glutamine entry into the tricarboxylic acid cycle (TCA), and may also sustain the energy required for cell membranes used for proliferation. The increased in fatty acid biosynthesis was also sustained from an upregulation of key genes involved in this process derived from a subset of microarray data from human ADPKD patients (12). However, the precise mechanism of how PC1 regulates the mitochondrial metabolism is still not precisely defined and understanding the origin of these perturbations including the role of the polycystin in the regulation of the mitochondrial function needs to be defined (please refer to Figure 2 for summary of the main metabolic pathways altered in ADPKD).

Glutamine is another important metabolite that sustains the supply of carbons and nitrogens to fuel biosynthesis of the TCA cycle metabolites (59). In standard culture, many cancer cell lines fuel the TCA cycle using acetyl-CoA produced from glucose and most of the anaeplerosis is supplied by glutamine (60). Glutamine addiction in ADPKD was first reported in the study by Hwang et al. In this study, a non-targeted metabolomics approach was investigated in autosomal recessive polycystic kidney disease (ARPKD) kidneys, and cpk (congenital polycystic kidneys) cells. The results were then validated via targeted analysis with changes in human ARPKD tissue and unaffected controls (61). Cpk cells are addicted to glutamine, which is required for the production of the oncometabolite glutamine-sourced 2-hydroxyglutarate (2-HG) (61). Accumulation of 2-HG has been described in renal cell carcinoma and it is thought to contribute to enhanced proliferation through epigenetic modifications (62). This striking parallel between cancer and ADPKD was firstly evidenced in this study (61) and subsequently associated with profound metabolic reprogramming that is found in tumors. However, ADPKD does not predispose to malignancy and the reader can find further details in the following review (63).

The glutamine addiction in ADPKD opened novel therapeutic opportunities, and subsequent studies have shown that inhibition of glutaminase 1 (GLS1) via BPTES or CB-839, tested in a less aggressive model of cystic disease (Aqp2-Cre:Pkd1^fl/fl and Pkhd1-Cre: Pkd1^fl/fl) (64), effected proliferation and cyst growth. The inhibition of glutamine with CB-839 resulted in cystic amelioration in Aqp2-Cre: Pkd1^fl/fl but not in Pkhd1-Cre: Pkd1^fl/fl mice. The investigators identified differences in signaling pathways due to mTORC1 and ERK activation, which might explain the likely failed inhibition, suggesting the upregulation of an adaptive metabolic pathway is able to bypass GLS1 inhibition. In another study by Podrini et al., tracing studies with [¹³C515N₂] glutamine revealed that Pkd1^−/− cells uptake more glutamine by utilizing the enzyme asparagine synthetase (ASNS) (12) (please refer to Figure 2). ASNS is a transamidase that converts aspartate into asparagine while deaminating glutamine to form glutamate (65). ASNS was found to be upregulated in cells lacking the Pkd1 gene, in cystic kidneys derived from Ksp-Cre:Pkd1^flox/−, and in a subset of microarrays from humans and murine kidneys when compared to the corresponding controls (12). To evaluate the relevance of ASNS upregulation in PKD, silencing Asns in Pkd1 devoid cells completely rescued the accumulation of α-ketoglutarate (α-KG), specifically reducing the contribution to glutamine-derived α-KG (12). One possible mechanism for the increased in ASNS is that asparagine synthesis supplies the availability of the TCA cycle intermediates and supplies the reduced nitrogen to maintain the pool of non-essential amino acid synthesis (66) but this needs to be investigated in ADPKD. In a metabolic profiling performed in children and young adults with ADPKD, Plasma samples were collected analysed with mass spectrometry (MS) and the most influential metabolite in ranked based area was asparagine, which was more than threefold higher in patients with ADPKD (67). In another study, glutamine addiction in PKD was investigated by an alternative glutamine pathway, via arginine synthetic enzyme arginosuccinate synthase1 (ASS1) directed to urea production (68). In both mouse models and human ADPKD tissue, the authors demonstrated that ASS1 expression was reduced and arginine depletion resulted in decreased cyst formation (68). Targeting arginine, via arginine-degrading enzymes, as used in clinical trials, and reviewed in Patil et al. (69), could be used to reduce circulating arginine in PKD. Collectively, these results suggest that ADPKD depends on glutamine for growth, shows increased asparagine synthetase activity, and its inhibition reduces cells growth (12).

Glutamine is also a precursor for the major antioxidant system compromised of glutathione (GSH) and oxidized glutathione (GSSG) (70). In another study by Flowers et al., the investigators found that embryonic Pkd1 mCCD are also dependent on glutamine, which is required for glutathione synthesis (71). The changes in glutathione metabolism and the vulnerability of mutant PKD cells to reactive oxygen species (ROS) was found at a very early stage of PKD, which was reflected by increased 8-hydroxydeoxyguanosine (8-OHdG) that enhanced disease progression (72). The oxidative stress biomarker 8-OHdG was increased in the kidney cyst-lining cells from Ksp-Cre:PKD1^flox/flox mice and Cy/+ rats, indicating that mitochondrial abnormalities also incite oxidative stress in these cells (52). There has been a link between oxidative stress and impaired endothelial-dependent relaxation (endothelial dysfunction) in progression of kidney injury with ADPKD, as observed in Nowak et al. (73) and Klawitter et al. (74). The PC1/PC2 complex is necessary for normal vasculature development, since it is required for endothelial cilia to sense fluid shear stress through complex biochemical cascades involving many factors including nitric oxide (NO) (74). NO is produced by endothelial cells and is a critical regulator of this balance, such that endothelial dysfunction is defined as reduced capacity for NO production (75). Endothelial dysfunction and decreased endothelial NO synthetase activity are observed in patients (74) and young adults with ADPKD (73). Because statins have anti-inflammatory and anti-oxidant effects (76), there have been studies for the prevention of acute kidney injury after cardiac surgery (77) which predisposes to endothelial dysfunction. In a pediatric ADPKD trial, plasma levels of oxidative stress biomarkers declined during pravastatin treatment but not with placebo (78). There is also an ongoing clinical trial in adults (Pravastatin in adult phase 4, ClinicalTrials.gov Identifier: NCT03273413). However, a post hoc analysis was performed on adults in the HALT-PKD trials on statins resulting in no benefit from statin therapy (79). Whether oxidative stress is a driver of disease still needs further investigation.

At the genome-scale level, metabolism is the result of thousands of compounds that are linked by reactions, which are continuously interacting with each other. The mathematical modeling process of metabolic networks can be broken in two steps. First, the stoichiometry of the system, which is the set of reactions representing the species connectivity, is established, and then rate laws are assigned to each reaction. For specific pathways, kinetic models based on sets of ordinary differential equations (ODEs) are broadly used to describe the metabolites' dynamic along time (80, 81). The foundation of this approach is the theory of molecular collisions that represents the basis of the mass action law. According to this theory, the algebraic expression for the ODEs depends on the reaction kinetics under consideration. There are several approaches for deriving kinetic functions: mass action kinetics (82), the Michaelis-Menten type and allosteric kinetics (83, 84), and the power-law approximation (85). The major drawback in using ODEs is the scarcity of experimental data on rate constants, especially at the genome-scale level. Genome-scale metabolic models require a large number of kinetic constants, many of which have not yet been experimentally measured. Moreover, the value of these parameters are subject to high uncertainty, resulting in erroneous simulations. Stoichiometric models address these problems by assuming that the changes in the compound concentrations are the result of the topological structure of the metabolic reactions. Starting from this assumption, by applying Flux Balance Analysis (FBA), a set of ODEs is transformed into a system of linear equations, and its rates can be obtained by solving a linear programming problem that optimizes specific objective functions (86). Further constraints are added to narrow the solution space. Although these types of models do not depend on the mathematical formalization of the rate laws, their analysis can lead to general results about the reactions properties. In one study (12), a computational systems-level approach based on FBA, called Differential Flux-balance Analysis (DFA) (87, 88), was employed to gather a broader understanding of the metabolic changes observed in Pkd1 mutant cells. By employing tracing experiments with ¹³C-labeled glucose, the investigators found an 1.6 fold increase in the uptake of glucose in Pkd1^−/− cells compared to controls. This data was used as mathematical constraint for DFA. The simulations suggested that an increased uptake of glucose is able to drive a statistically significant change of the bioenergetics mechanisms, such as the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid synthesis and oxidation. The simulations have been followed by an extensive study of the observed metabolic reprogramming by integrating in vitro and in vivo analysis with metabolomics and transcriptomics data. In a subsequent work (89), DFA has been applied to test whether these alterations are causally interconnected or if they might occur simultaneously without interfering with each other. Particularly, DFA has been integrated with a Compounds-Pathways Enrichment Analysis to simulate the metabolic changes of bioenergetics pathways observed in Podrini et al. (12): (i) increased glucose uptake; (ii) increased mitochondrial glutamine uptake; (iii) increased fatty acids synthesis; (iv) reduced fatty acids oxidation. They found that simulations of these alterations result in important overall metabolic changes in pathways that are very similar in the different conditions, suggesting that they are all interconnected by key genes and specific chemical reactions. However, slightly different alterations were observed in the different simulations and only increased glycolysis appears to be the alteration that better recapitulates simultaneously all changes observed in Pkd1 mutant cells, while none of the other simulations can recapitulate the overall picture, suggesting an important possible causal link and directionality of the alterations observed. In addition, DFA showed that an increased flux of citrate from mitochondria to cytosol modulates the switch toward alternative bioenergetics pathways, hence, this metabolite could be one of the key factors in the regulation of the metabolic alterations observed in ADPKD.

Computational analysis may contribute to basic research on ADPKD, but the success of this approach will certainly require new modeling and simulation tools because our current understanding of how regulations are carried out is probably still missing several significant pieces. More experimental work is needed, and these experimental results must be incorporated in improved mathematical models, which would benefit from the creation of a common modeling framework that takes into account different entities, such as genes, proteins, and metabolites, and relationships, like metabolic reactions, interactions, regulations, and transports. Several problems and requirements arise toward this strategy, such as how to deal with incomplete information, how to manipulate large models, how to extract valuable information about the regulative mechanisms, how to analyze these models, and how to infer suitable models from experimental data.

The pathophysiology behind ADPKD is not completely understood, but a “threshold model” of cytogenesis is supported by previous studies (101–103). In this model, reduction of cellular levels of PC1 can influence cystic disease severity by a complexity of signaling pathways (104). However, re-establishing the levels of PC1 to restore normal cystic tissue remains an elusive approach. Targeting altered signaling pathways that drive cytogenesis (104) may be the preferred strategic approach to ameliorate disease progression in ADPKD. As a consequence of vasopressin V2-receptor activation, dyregulated signaling pathways in ADPKD such as increased cyclic adenosine monophosphate (cAMP) concentration, resulted in the identification of tolvaptan as a first treatment for ADPKD (105, 106). The activity of key energy metabolic enzymes was shown to be central in the metabolic shift of ADPKD. For example, AMP-activated protein kinase (AMPK) decreased (9, 107), while mTORC1 and ERK increased (108, 109). It was proposed that the decreased phosphorylation of AMPK is due to regulation of the liver kinase B1 (LKB1)/AMPK axis (9, 16). In another study, it was reported that the activation of the mitogen-activated protein kinase (MAPK)-ERK pathway was observed in an acute perinatal PKD model; however, an inhibitor against ERK was not able to prevent cyst formation and may not be the basis for cyst expansion (110). Inhibitors of the mTORC1 complex, including sirolimus and everolimus, have been tested in five clinical trials. The results of the clinical trials showed no beneficial effects on the rate of change of total kidney volume (TKV) (111).

A novel therapeutic approach that targets mRNA expression is to utilize the action of an antisense oligonucleotide (ASO), a single-stranded deoxyribonucleotide that is complimentary to the mRNA target. The goal of the ASO is the down regulation of a specific molecular target (112–114). Therapeutic use of ASOs has been approved by the FDA for various pathologies (115). An ASO target strategy has been tested by chronic administration of mTORC1 ASO in Pkd2^W25/− mice, a homologous model of human PKD caused by a mutation in the Pkd2 gene, and resulted in improvement of the renal cystic phenotype (116). ADPKD also effects endothelial dysfunction (117) and circulating bioactive lipid mediators (118) which can contribute to metabolic disorders. From a clinical point of view, there is a higher incidence of new onset of diabetes mellitus after transplantation in recipients with ADPKD vs. other primary kidney diseases (119). To tackle a broad range of metabolic disorders in relation to vascular damage in ADPKD, clinical trials have been conducted with angiotensin-converting enzyme (ACE) inhibitors in ADPKD patients (31, 67). These trials have not been successful in decreasing renal function (120). Alternatively, the use of ASO against angiotensin (AGT) has been investigated in pre-clinical studies (116, 121, 122). The ASOs resulted in an improved cystic phenotype in the Pkd2^WS25 model (123) and in the global (121) and in the tamoxifen-inducible knockout model of PKD (122). This suggests that targeting AGT with ASO may be more efficient than ACE inhibitors, and could open novel therapeutic opportunities for targeting abnormal signaling cyst formation in ADPKD.

The inhibition of mitochondrial function by anti-miR~17-92 attenuates disease progression in ADPKD mouse models irrespective of the mutated gene (Pkd1 or Pkd2), the type of mutation (null or hypomorphic) or the dynamics of cyst growth (54). An anti-miR-17 oligonucleotide has proved to be efficient in reducing cyst formation in PKD mouse models (54, 124). Based on these results, anti-miR-17 oligonucleotides were designed and screened with favorable pharmaceutical properties (125). In fact, a phase 1 trial with an anti-miR-17 drug (RGLS4326) is currently being performed in ADPKD patients (ClinicalTrials.gov Identifier: NCT04536688). The miR-17 family is a promising drug target for ADPKD. Recent evidence shows that large clusters of transcriptional enhancers, super-enhancers (SE), undergo extensive remodeling during cytogenesis and that SE-associated transcripts are most enriched for metabolic genes in cystic cells (126). AMP deaminase 3 (AMPD3), a key enzyme involved in AMP metabolism and AMPK activation, was found to be SE-driven in cyst development. Inhibiting AMPD3 by pentostatin, or cyclic dependent kinase 7 (CDK7), one of the controlled metabolic target genes, decreased cell proliferation and apoptosis in ADPKD cells and delayed disease progression in tamoxifen-inducible Pkd1 mice with slowly progressing ADPKD (126). These findings suggest that CDK7- containing SEs are critical in ADPKD. As for therapy, inhibiting AMPD3, could be beneficial to target before disease progression and can provide a greater efficacy than targeting the downstream effectors in ADPKD (please refer to Figure 3 for an overview of therapeutical targets).

Recent preclinical data have generated promising results for targeting cellular bio-energetics in ADPKD. The high rate of glycolysis encountered in ADPKD has been targeted with glucose analog 2-DG in orthologous mouse models of ADPKD (9, 107, 127) with effective cystic amelioration. A phase 1 clinical trial has been designed with 2-DG in an ADPKD cohort (128). In addition, the dependence on glucose in cystic cells opened new venues to target disease by modifying diet for cystic amelioration. In fact, 2-DG can be compared to calorie restriction without reducing food intake given its capability to reduce metabolic rate addiction to glucose (129). Thus, ketogenic diets that decrease glucose availability have been tested in ADPKD, with the hypothesis that ketogenesis may be beneficial in preventing cyst formation. This hypothesis was evaluated in an ADPKD rat model and in a spontaneous feline model of ADPKD, where a high ketogenic diet resulted in strong inhibition of PKD progression (39). The increase in ketosis was also investigated by acute fasting in mouse, rat, and feline models of PKD and significantly reduced renal cystic burden in all three models (39). Currently, there is an on-going clinical trial on the short term induction of ketosis in ADPKD patients (ClinicalTrials.gov Identifier: NCT04472624) and also the patent-pending supplements are also being formulated and will be tested in the near future in clinical trials (130). Furthermore, prior to testing the ketogenic diet calorie restriction was found to reduce cyst growth (131, 132). There is growing evidence that diet manipulation can be a modifier of ADPKD disease and that the plethora of metabolic dysregulation observed in ADPKD may support the proliferating cyst epithelia. One possible mechanism is through the impact of one-carbon and methionine metabolism which generate the essential methyl groups for which altered nutrient utilization is facilitated. Ramalingam et al. found a higher methionine-S-adenosyl methionine (SAM) levels and methyltransferase-like 3 (Mettl3) upregulation in multiple ADPKD mouse models and that methionine-SAM supplementation or Mettl3 overexpression induced cyst growth (133). Dietary methionine restriction or Mettl3 ablation attenuated PKD, which may be regulated through epitranscriptomic mechanism through c-Myc and cAMP signaling activation (133). As for therapy, a vegan-based diet could also be used to ameliorate cyst formation, as methionine is found in meat and fish; alternatively, METTL3 inhibitors may also be targetable for ADPKD but warrants further investigation.

Tolvaptan, as already mentioned, is the unique drug that has been approved, in several countries, for the treatment of ADPKD (134). Frequent liver chemistry monitoring is suggested for patients using Tolvaptan, as it caused liver enzyme elevations in two pivotal Phase III clinical trials in ADPKD patients (42, 106). Taking into account this information, there is an urgent need for new compounds that can be used to stop the disorder progression.

A novel approach for identifying new drugs for ADPKD has been investigated by Malas et al. (14). Their approach combines integrated computational tools, repurposing analysis, cheminformatics data, and RNA sequencing of Pkd1 KO mice at different disease stages in order to identify new drugs for ADPKD. Results from this approach indicated that three compounds (i.e., Meclofenamic acid, Gamolenic acid, and Birinapant) are able to inhibit cyst swelling in vitro without toxicity, and could be further investigated for the treatment of ADPKD. Meclofenamic acid targets the aldo-keto reductase family 1, which is involved in steroid metabolism (135), a pathway known to be a player in cyst development in a PKD rat model (136). Gamolenic acid has been selected based on PPARδ, a nuclear hormone receptor that controls a set of metabolic genes belonging to glucose metabolism, and fatty acid synthesis, storage, mobilization, and catabolism. Members of the PPAR family have been studied in pre-clinical trials for PKD (55, 137). Birinapant represents a second mitochondrial-derived activator of caspases (SMAC) mimetic that modulates apoptosis (138). It has been found that the SMAC mimetic GT13072 reduces PKD progression in a Pkd1 mouse model (139).

Lixivaptan, another vasopressin V₂ receptor antagonist, was proposed for ADPKD treatment. This compound was initially developed for treating hyponetremia (140), and it has been evaluated by applying quantitative systems toxicology modeling (141). Their results showed that when compared to Tolvaptan, Lixivaptan had a significantly lower risk of hepatotoxicity at their respective doses for ADPKD treatment; therefore, it is a good candidate for continued study in the treatment of this disorder. The difference in the toxicity mechanisms between Tolvaptan and Lixivaptan demonstrates the fact that even compounds within the same class can vary widely in terms of potential liability and potential mechanisms of toxicity.

Based on drug repositioning, Asawa et al. developed a high-throughput screening platform for ADPKD (13) that employs Pkd1-null postnatal cells of proximal tubule origin, Pkd1-null mouse embryonic kidney cells of collecting duct origin (MEK-null), and Pkd1^−/− human kidney epithelial cells in order to evaluate a set of 8814 approved drugs and studied compounds principally having anti-neoplastic usage. It resulted in 155 compounds that reduced the viability of mutant cells but had minimal effects on wild-type cells. The investigators inferred that 109 of these compounds reduced cyst growth in Pkd1^−/− cells cultured in a 3D matrix. Furthermore, with the aim of screening out possible therapies that failed to be translated in the treatment of the human disease, the platform has been extended by introducing the evaluation of the compounds in a panel of primary ADPKD and control human kidney epithelial cells. This step allowed the repurposing of 18 compounds that affected the viability of ADPKD cells with minimal effects on control human kidney epithelial cells. These compounds are: (i) Briciclib, Prexasertib, AHPN, and IMD-0354 which have been not yet been analyzed in the context of ADPKD; (ii) Cytarabine, Ancitabine, Clofarabine, Gemcitabine, Adefovir, and Topotecan, Belotecan, and 9-Methoxycamptothecin, which inhibit the proliferation of Pkd1^−/− cells by directly interfering with DNA replication; (iii) Combretastatin A-4, Leptomycin B, Delanzomib, CB30865, Cerivastatin, and Pitavastatin which have been previously proposed as potential therapeutic options for ADPKD (142–144).

In short, given the complexity of the altered pathways in cyst-lining epithelia, and the availability of a broad range of potential targets, powerful strategies are needed to make faster advances in this field. Systems medicine and drug repurposing for the development of new treatments can help expedite the discovery of new effective treatments. The tools and the approaches presented in this section represent valuable platforms to repurpose chemical compounds and to identify drug targets for ADPKD treatment. All the presented studies discussed are of high relevance to ADPKD patients, as Tolvaptan, is the only approved therapy but has limited treatment options. The identified compounds represent a starting point for future efficacy studies employing relevant ex vivo and in vivo ADPKD models.